Prulifloxacin - Nippon Shinyaku
Alternative Names: AF 3012; NAD-441A; NM441; OPT-99; PrulifloxacinA brs; Pruvel; Quisnon; Sword; Sword 100; UnidroxLatest Information Update: 14 Nov 2018
Price :
$50 *
At a glance
- Originator Nippon Shinyaku
- Developer Angelini Group; Cubist Pharmaceuticals; Lee's Pharmaceutical; Merck & Co; Nippon Shinyaku; Optimer Pharmaceuticals
- Class Antibacterials; Dioxolanes; Fluoroquinolones; Piperazines; Quinolones; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute exacerbations of chronic bronchitis; Bacterial infections; Gram-negative infections; Gram-positive infections; Pneumonia; Respiratory tract infections; Urinary tract infections
- Phase III Prostatitis; Traveller's diarrhoea
Most Recent Events
- 14 Nov 2018 Launched for Acute exacerbations of chronic bronchitis in China (PO) prior to November 2018 (Lees Pharmaceutical Holdings website, November 2018)
- 01 Jul 2015 Lees Pharmaceutical completes a phase III trial in Urinary tract infections in China (NCT02439632)
- 13 May 2015 Prulifloxacin is still in phase-III development for Prostatitis, Traveller's diarrhoea and Acute exacerbations of chronic bronchitis in Italy